C
Champions Oncology
Personalize Each Patient窶冱 Cancer Treatment Therapy
About Champions Oncology
In 2007, Johns Hopkins oncologist Dr. David Sidransky founded Champions Oncology with a core mission: to personalize cancer treatment. The company centered its work on an innovative concept known as mouse avatars, or TumorGrafts. This process involves implanting a living sample of a patient's tumor into an immunodeficient mouse. Once the tumor grows, it's propagated into more mice, which are then used to test various cancer drugs and combinations to see what is most effective against that specific tumor. The company's journey began to take a significant turn when it acquired Biomerk, Inc. in May 2007, sharpening its focus on this new line of business. Initially named Champions Biotechnology, it rebranded to Champions Oncology in 2011 to better reflect its strategic direction. The company went public, trading on the NASDAQ under the symbol CSBR. A notable public offering in June 2016 raised approximately $4.39 million, which was earmarked for the development of its TumorGraft platform and for working capital. Champions Oncology operates primarily as a contract research organization (CRO), providing preclinical research services to pharmaceutical and biotech firms. This model allows drug developers to outsource complex tumor studies, leveraging Champions' specialized platform. Today, the company continues to innovate, expanding its services and presenting its research at major scientific conferences, solidifying its role in the advancement of personalized oncology.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2003
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Champions Oncology in the Herzliya ecosystem
The Champions Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Champions Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Champions Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

